Lumos Diagnostics Holdings (ASX:LDX) agreed with Interlux Group for the sale of the company's point-of-care respiratory test, FebriDx, across the Baltic region, according to a Thursday filing with the Australian bourse.
Interlux will be responsible for the sale, distribution, and inventory management of FebriDx, and has placed an initial stocking order to support its immediate availability across the region, the filing said.
Shares of the company rose 4% on market close.